[Antihypertensive therapy and drug-drug interactions]

Détails

ID Serval
serval:BIB_8C7F0B579BB6
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
[Antihypertensive therapy and drug-drug interactions]
Périodique
Rev Med Suisse
Auteur(s)
Girardin F., Pechere-Bertschi A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2005
Volume
1
Numéro
32
Pages
2099-100, 2102-4
Langue
français
Notes
Girardin, F
Pechere-Bertschi, A
fre
English Abstract
Review
Switzerland
Rev Med Suisse. 2005 Sep 14;1(32):2099-100, 2102-4.
Résumé
Adverse drug reactions (ADR) have increasing clinical implications and are a permanent challenge for general practitioners. Data suggest that ADR cause 3 to 18% of all hospital admissions with potentially serious consequences. Polymedication, female sex, multiple pathologies with age-related changes are predisposing factors. Antihypertensive drugs with a low bioavailability, a high protein binding capacity and specific elimination pathways are particularly prone to pharmacokinetic interactions. ACE-inhibitors, atenolol, moxonidine and diuretics have few pharmacokinetic interactions. Calcium channel blockers and beta-blockers are associated with an increased risk of pharmacokinetic drug-drug interactions. Diltiazem and verapamil are particularly prone to interactions, as they strongly inhibit the elimination of drugs undergoing the CYP3A4 and P-glycoprotein pathways.
Mots-clé
Antihypertensive Agents/*adverse effects/metabolism, Cytochrome P-450 Enzyme System/metabolism, Drug Interactions, Humans
Pubmed
Création de la notice
10/02/2021 12:32
Dernière modification de la notice
11/02/2021 7:26
Données d'usage